Clene plans Q3 2026 NDA submission for CNM-Au8 ALS; Q1 net loss $8.1M, cash $5.9M

Clene Inc.

FDA Type C meeting confirmed data may support NDA under accelerated approval for ALS; submission planned Q3 2026.
May 2026: Amended $10M convertible debt; maturity extended to Aug 2027, monthly payments cancelled.
Q1 2026 net loss $8.1M ($0.69/share) vs $0.8M loss in Q1 2025; R&D down, other expense up from financing.
Cash $5.9M at Mar 31; with $7M May offering and $7M warrant exercises, runway expected into 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.